Can-Fite BioPharma Ltd. (CANF)
NYSE American · Healthcare · Biotechnology
$2.14−1.92%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $6.5M
- 52-week range
- $2.12 – $12.60
- 52-week change
- −81.83%
- EPS (trailing)
- −$13.23
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $405K (−39.91%)
- Net income
- −$9.8M
- Operating margin
- −2456.8%
- Diluted EPS
- −$5.97
- Free cash flow
- −$8.9M
From the company’s annual report on SEC EDGAR.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
Headquarters: Ramat Gan, Israel · 5 employees · canfite.com